PPARα contributes to colonic protection in mice with DSS-induced colitis.
Inflammatory bowel disease (IBD) is characterized by repeated chronic inflammation of the gastrointestinal tract. We have used the complementary model of colonic inflammation to examine the roles of peroxisome proliferator-activated receptor α (PPARα) in colonic inflammation and thus its possible role in IBD. We characterized an innate immune-mediated model of colitis induced by dextran sulfate sodium (DSS). Mice with DSS-induced colitis were injected with Wy-14643 (2 mg/kg) as a PPARα agonist every day from day 0 to day 5. We show that mice given Wy-14643 were less susceptible to experimental acute colitis induced by DSS, and this decreased susceptibility was correlated with decreased production of IFNγ, IL-1β, IL-6, and TNF-α. Our findings suggest that PPARα has a role in controlling colonic inflammation and mucosal tissue homeostasis.
Azuma
Yasu-Taka
YT
Laboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Science, Izumisano, Osaka 598-8531, Japan. azuma@vet.osakafu-u.ac.jp
Nishiyama
Kazuhiro
K
Matsuo
Yukiko
Y
Kuwamura
Mitsuru
M
Morioka
Ai
A
Nakajima
Hidemitsu
H
Takeuchi
Tadayoshi
T
D000818:Animals; D003092:Colitis / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D003106:Colon / Q000187:drug effects / Q000473:pathology; D016264:Dextran Sulfate / Q000633:toxicity*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D051379:Mice; D047493:PPAR alpha / Q000819:agonists* / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*
D047493:PPAR alpha; D011743:Pyrimidines; C006253:pirinixic acid; D016264:Dextran Sulfate